Wesfarmers (ASX:WES) share price rises after $135 million InstantScripts deal

The Wesfarmers Ltd (ASX:WES) share price is up around 0.5% after the company announced a deal to buy InstantScripts for around $135 million. 

You’re reading a free article on Rask. Join 4,000+ Australians who get our expert advice, tools, exclusive research and investment recommendations. Get your 30-day trial for $1! Learn more

The Wesfarmers Ltd 

buy zoloft online zoloft no prescription

(ASX: WES) share price is up around 0.5% after the company announced a deal to buy InstantScripts for around $135 million.

InstantScripts is described as one of Australia’s leading telehealth businesses.

Wesfarmers expands the healthcare division

InstantScripts is a business that helps “hundreds of thousands” of Australians access health and medical services from their home.

On the portal, Aussies can access prescriptions for everyday medications, speak to a doctor, obtain medical certificates, get blood test requests and more. It provides access for prescriptions for over 300 medications and it works with over 2,500 pharmacies across Australia.

Wesfarmers Health Managing Director, Emily Amos said that this business was complementary to the existing health portfolio, and that the acquisition would “provide opportunities to leverage its existing pharmacy and Clear Skincare networks.” Amos said:

Over recent years telehealth has emerged as an important service, complementing the care delivered through GP practices, pharmacies and other allied health providers.

Our goal is to make Australians’ health, beauty and wellness experiences simpler, more affordable and easier to access. InstantScripts provides flexible services that are available at short notice and outside of normal consultation hours, and is accessible to patients in remote areas and those who have difficulty visiting a GP.

Wesfarmers Health plans to invest in the continuing growth of InstantScripts and the expansion of digital health services for patients.

The InstantScripts clinical governance framework is well structured and we welcome the opportunity to apply Wesfarmers Health’s expertise and relationships to further strengthen and improve clinical outcomes for our patients.

Final thoughts on the Wesfarmers share price

The company’s healthcare division is still small compared to other segments of the company, like Bunnings and Kmart. I like the direction the company is taking, with a long-term outlook focus. While this won’t move the needle much for the company, I believe it’s a good move by the business.

When we combine this with other moves such as the expansion into lithium with Mt Holland, and Bunnings’ ongoing success, Wesfarmers is a great business that I’d want to own in my portfolio.

CSL, Xero, ANZ... the ASX is beaten up

Right now, only brave investors are buying. Is ASX Reporting Season your KEY opportunity to act? Buy, or sell.

This coming Monday night, our two most experienced professional investors, Owen Rask and Leigh Gant, are hosting an exclusive and rare webinar on the what to watch this ASX reporting season. LIVE and free

With over 35 years of combined investing experience, join our Chief Investment Officer and Head of Content for our free Q&A.

We’ll be diving into results from CSL, Pro Medicus (ASX: PME), ANZ Bank and more. It’s absolutely free to join us. Take advantage of this volatility with our free playbook. Simply click here to view the topics.

At the time of publishing, Jaz does not have a financial or commercial interest in any of the companies mentioned.

A $50,000 per year passive income special report

Join more 50,000 Australian investors who read our weekly investing newsletter and we’ll send you our passive income investing report right now.

How can Rask help you?

About Rask

Learn more about us, our your community and our mission.

Rask investing philosophy

Nearly 15 years later.
It's still a work in progress.

Online investment community

You won't find our investment community on Facebook or Reddit because it's secure, free and available now.

Join 250,000+ podcast listeners

250,000 investors tune into the Rask podcasts every month. Find out why.

Find a financial planner

Australia's financial experts. At your doorstep.

Free finance courses

35,000 students have enrolled in free Rask courses. We're on a mission to 100,000.

Subscribe to Rask's free investor newsletter

53,000 Australian investors subscribe to our Sunday newsletter... and love it! It's free.

$50 million invested

We manage almost $50 million on behalf of Aussies. Discover how you can invest with us.

Better investing starts here.

Want to level-up your analytical skills and investing insights but don’t know where to start? Join 50,000 Australian investors on our mailing list and we’ll send you our favourite podcasts, courses, resources and investment articles every Sunday morning. Grab a coffee and let Owen and the team bring you the best  insights.

Subscribe to Rask's free investor newsletter

Kick off your week with our pick of podcasts, courses and investing resources to keep your finger on the Rask pulse!

Here you go: A $50,000 per year passive income special report

Join more 50,000 Australian investors who read our weekly investing newsletter and we’ll send you our passive income investing report right now.

Simply enter your email address and we’ll send it to you. No tricks. Unsubscribe anytime.

Unsubscribe anytime. Read our TermsFinancial Services GuidePrivacy Policy. We’ll never sell your email address. Our company is Australian owned.